chloroquine and derivatives - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.43 [0.49, 4.21]< 10%2 studies (2/-)25.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.21 [0.69, 2.12]< 10%1 study (1/-)25.2 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 0.83 [0.47, 1.44]> 10%1 study (1/-)25.1 %some concernnot evaluable moderateimportant-
viral clearance 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-

safety endpoints 00

adverse events 0.89 [0.31, 2.57]< 10%2 studies (2/-)58.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.